SEC Accepts GenoMed's Registration Statement
ST. LOUIS, Nov. 8 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that the Securities and Exchange Commission has verbally provided notification to the Company that the Company's Form 10-SB Registration Statement has been declared effective as of November 7, 2002.
The Company now plans to make the necessary application to request that its common stock be quoted on the Over The Counter Bulletin Board (OTC Bulletin Board).
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use.
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
+1-877-436-6633, or fax, +1-314-977-0042, or kfischer@genomedics.com
Web site: genomedics.com
. |
